Analyses of A-MuLV transformed cell lines have provided fundamental insights into the molecular mechanisms which control the rearrangement events leading to the expression of specific antigen receptor genes. These studies have clearly indicated that tissue-specific, developmental stage-specific, and allelically excluded assembly of Ig H and L chain and TCR variable region genes are very strictly regulated processes and, furthermore, that this regulation probably is effected at the level of the accessibility of the individual sets of V gene segments to a common recombinase. More preliminary studies have also suggested that accessibility targeting may be involved in the regulation of directed Ig H chain class-switch recombination events. Currently, we do not understand the nature of "accessible" DNA sequences and we have little understanding of the molecular mechanisms by which Ig (and potentially TCR) chains mediate the regulation of specific recombination events by signaling changes in the accessibility of the various loci. However, an ideal model system for the analysis of these questions is currently available in the form of A-MuLV transformed pre-B cell lines which, in a properly regulated fashion, undergo all of the various recombination events associated with the pre-B stage of B cell differentiation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-065x.1986.tb01470.x | DOI Listing |
Naturwissenschaften
January 2025
Department of Biology, University of Washington, Seattle, WA, 98195, USA.
Four main classes of introns (group I, group II, spliceosomal, and archaeal) have been reported for all major types of RNA from nuclei and organelles of a wide range of taxa. When and how introns inserted within the genic regions of genomes, however, is often unclear. Introns were examined from Archaea, Bacteria, and Eukarya.
View Article and Find Full Text PDFJ Antimicrob Chemother
January 2025
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Background: Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1.
View Article and Find Full Text PDFInt J Gynecol Cancer
January 2025
Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China; Fudan University, Shanghai Medical College, Department of Oncology, Shanghai, China. Electronic address:
Objective: Homologous recombination deficiency assays, guiding treatment of poly (adenosine diphosphate ribose) polymerase inhibitors, are increasingly applied in clinics. This study aimed to evaluate the predictive performance of homologous recombination deficiency status at genomic and functional perspective on the efficacy of platinum-based chemotherapy in ovarian cancer.
Methods: Between 2016 and 2019, 134 patients with high-grade ovarian cancer were retrospectively analyzed.
Mycobacteriophages are viruses that specifically infect bacteria of the Mycobacterium genus. A substantial collection of mycobacteriophages has been isolated and characterized, offering valuable insights into their diversity and evolution. This collection also holds significant potential for therapeutic applications, particularly as an alternative to antibiotics in combating drug-resistant bacterial strains.
View Article and Find Full Text PDFJ Infect
January 2025
Research Your Health, 6020 West Parker Road, Suite 430, Plano, Texas, 75093, USA.
Objectives: Safety and immunogenicity assessment of updated monovalent and bivalent SARS-CoV-2 vaccines in adolescents.
Methods: This phase 3, double-blinded study randomised 12-<18-year-old participants, who received ≥2 prior doses of an approved/authorised mRNA-based COVID-19 vaccine, 1:1 to receive NVX-CoV2601 (XBB.1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!